Universal Beteiligungs und Servicegesellschaft mbH Takes $12.37 Million Position in Glaukos Co. (NYSE:GKOS)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Glaukos Co. (NYSE:GKOS - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 82,477 shares of the medical instruments supplier's stock, valued at approximately $12,367,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.15% of Glaukos at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Barclays PLC raised its holdings in Glaukos by 394.4% in the 3rd quarter. Barclays PLC now owns 89,699 shares of the medical instruments supplier's stock valued at $11,686,000 after acquiring an additional 71,556 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Glaukos by 42.1% in the fourth quarter. SG Americas Securities LLC now owns 3,641 shares of the medical instruments supplier's stock valued at $546,000 after purchasing an additional 1,078 shares during the last quarter. KBC Group NV lifted its position in Glaukos by 67.3% during the fourth quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock worth $362,000 after buying an additional 972 shares in the last quarter. Empowered Funds LLC purchased a new position in Glaukos during the fourth quarter worth approximately $236,000. Finally, Louisiana State Employees Retirement System grew its holdings in Glaukos by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier's stock valued at $4,003,000 after buying an additional 100 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Insider Buying and Selling

In related news, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the transaction, the chief financial officer now directly owns 53,431 shares of the company's stock, valued at $5,708,568.04. This trade represents a 2.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 6.40% of the company's stock.

Wall Street Analyst Weigh In

GKOS has been the topic of several recent research reports. Truist Financial reissued a "buy" rating and set a $135.00 price target (down previously from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. Morgan Stanley dropped their price target on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Mizuho cut their price target on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a report on Wednesday, April 16th. Needham & Company LLC decreased their price objective on Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Finally, Piper Sandler lowered their price objective on Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a research report on Tuesday, April 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, Glaukos currently has an average rating of "Moderate Buy" and an average target price of $134.67.

Glaukos Stock Down 0.6%

Glaukos stock traded down $0.54 during mid-day trading on Friday, reaching $94.33. 1,146,074 shares of the company's stock were exchanged, compared to its average volume of 707,621. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos Co. has a twelve month low of $77.10 and a twelve month high of $163.71. The company has a market cap of $5.39 billion, a P/E ratio of -32.87 and a beta of 0.83. The company has a fifty day moving average of $92.61 and a 200-day moving average of $123.02.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.11. The firm had revenue of $106.66 million during the quarter, compared to analysts' expectations of $102.78 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Glaukos's revenue for the quarter was up 24.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.70) EPS. Sell-side analysts expect that Glaukos Co. will post -1.08 EPS for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.